ENSC — Ensysce Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1716947 ·
Last close
$0.38
Market Cap
$7.47M
52W High
$2.04
52W Low
$0.23
ADV30
473,844
Next earnings
—
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,576,389 -2,570,709 2,957,273 676,704 4,068,106
Mar 2026 0 — -3,562,230 -3,556,415 2,167,803 745,482 2,836,815
Dec 2025 0 — -2,781,825 -2,767,648 7,452,479 4,310,354 4,567,729
Sep 2025 0 — -3,741,095 -3,729,128 3,179,464 1,673,218 2,304,750

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,855,395
Investing CF
$0
Financing CF
$7,444,167
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.76
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-145,847,123
Inventory
—
Receivables
$416,811
ST Investments
—
EBIT TTM
$-12,608,393
Pretax Income TTM
$-12,624,387
Interest Exp TTM
$15,994
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,500,753
EBITDA
—
Free Cash Flow
$-4,151,424
Enterprise Value
$6,724,672
Total Cash
$676,704
Total Debt
$196,842
Shares Out
19,456,794
Trailing EPS
$-2.47
Book Value
$0.70
ROE
-1295.1%
ROA
-185.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -10,240,946 -10,175,700 7,452,479 4,567,729 3,213,720 -7,806,292
Dec 2024 0 -6,730,134 -7,986,935 5,597,232 2,217,293 3,708,422 -7,502,700
Dec 2023 0 -10,718,187 -10,613,074 2,708,085 3,359,352 -322,858 -10,779,982
Dec 2022 0 -24,222,095 -24,172,292 5,885,052 9,914,704 -3,714,444 -17,887,439

TTM Snapshot

Revenues TTM
$4,500,754
NetIncome TTM
$-12,623,900
OpCashFlow TTM
—
Assets (Latest)
$2,957,273
Forward EPS
$-0.05

Peers — same industry

TickerNameMarket CapLastDaily %
CURX Curanex Pharmaceuticals Inc $7.37M $4.70 —
BFRG BullFrog AI Holdings, Inc. $7.59M $0.41 —
UPC Universe Pharmaceuticals INC $7.81M $1.56 —
XCUR EXICURE, INC. $7.07M $1.08 —
RKTO Rocket One Inc. $7.89M $0.32 —

News headlines (Yahoo Finance, 1h cache)

Ensysce Biosciences Announces Participation in Upcoming Investor Conferences
2026-11-16 21:15 · Yahoo
ENSC Improves Prospects with Transformational Quarter
2026-11-13 11:01 · Yahoo
Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-12 21:15 · Yahoo
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
2026-10-21 12:00 · Yahoo
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
2026-09-24 12:00 · Yahoo
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
2026-09-15 13:15 · Yahoo
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
2026-09-14 12:00 · Yahoo
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
2026-09-02 12:30 · Yahoo
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
2026-08-31 12:30 · Yahoo
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
2026-08-20 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.